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E-mail address: santi.spampinato@unibo.it (S. SpaProlonged (12 h) exposure of SH-SY5Y neuroblastoma cells to the mu-opioid receptor (MOPr) ago-
nist [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) causes homologous desensitization as well
as heterologous desensitization of the extracellular signal-regulated kinase 1/2 (ERK 1/2) phosphor-
ylation induced by insulin-like growth factor (IGF)-I. Brief (15 min) but not prolonged exposure to
DAMGO transregulates the insulin-like growth factor-I (IGF-I) receptor, as evidenced by its phos-
phorylation in the absence of IGF-I. Silencing of b-arrestin 2 uncouples the crosstalk between the
two receptors, thus maintaining IGF-I-mediated receptor phosphorylation and ERK 1/2 activation
even after prolonged DAMGO exposure. Furthermore, MOPr-induced activation of IGF-I receptor
requires the tyrosine kinase c-Src.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ing to opioid-induced cellular responses [3]. MOPr-stimulatedOpioids are commonly used for pain relief. However, prolonged
administration of opioids may cause tolerance and dependence,
which limits their use [1]. At the molecular level, opioid-mediated
analgesia is mainly achieved by agonist-induced activation of the
mu-opioid receptor (MOPr), a G-protein coupled receptor (GPCR).
This event generates a cascade of intracellular signals that affect
several cytoplasmic and nuclear targets [1]. An important signaling
pathway activated by MOPr is the extracellular signal-regulated ki-
nase (ERK) pathway, speciﬁcally ERK 1/2, belonging to the family of
mitogen-activated protein-kinases (MAPK) [2]. This pathway tar-
gets multiple transcriptional factors for expression or repression
of genes, and produces changes in cellular phenotypes, contribut-chemical Societies. Published by E
GO, [D-Ala2,N-Me-Phe4,Gly5-
ermal growth factor receptor;
S, fetal calf serum; GPCR, G-
factor-I; IGF-IR, insulin-like
protein-kinases; MOPr, mu-
K 1/2, phosphorylated extra-
-(4-chlorophenyl)-7-(t-butyl)
insulin-like growth factor I
ll interfering RNA; tERK 1/2,
IR, total insulin-like growth
mpinato).ERK 1/2 phosphorylation closely resembles signaling by receptor
tyrosine kinases (RTKs) [3]. A key ﬁnding in unraveling this puzzle
was the discovery that MOPr agonists are able to transactivate at
least one RTK, that for epidermal growth factor (EGFR) [4]. This ef-
fect is shared with d-opioid receptor agonists [5] and other GPCR
agonists [2].
A very important intermediate of the signaling ﬂow from GPCR
to RTK are b-arrestins, which play a fundamental role in GPCR sig-
naling, participating in cytoplasmic signal transduction [6,7]. Based
on the properties of b-arrestins as signaling adaptors and scaffolds,
Xiao et al. [8] extensively analyzed their molecular interactions,
and identiﬁed them as hub proteins in cytoplasmic signal distribu-
tion and progression. Bohn et al. [9] reported that b-arrestin 2
knockout mice display increased analgesia in response to mor-
phine, demonstrating the crucial role of this protein in opioid
receptor function. In fact, b-arrestin 2 regulates the constitutive
activity and recycling of MOPr through acting as a scaffold for
the tyrosine kinase c-Src or for ERK 1/2 [10]. Myiatake et al. [11]
recently reported that the MOPr stimulation-dependent phosphor-
ylation of EGFR strictly relies on b-arrestin 2 signaling pathways in
astrocytes.
b-Arrestins contribute to opioid receptor desensitization, a phe-
nomenon that reﬂects the gradual decrease in receptor activity
during prolonged agonist treatment and that has been implicated
in tolerance development [12]. Therefore, it could be hypothesized
that b-arrestin translocation to receptors exposed to agonists [13]lsevier B.V. All rights reserved.
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activation of RTKs.
The insulin-like growth factor I receptor (IGF-IR) belongs to the
RTK family. IGF-I and IGF-II bind to this receptor and mediate its
autophosphorylation, which allows downstream recruitment of
adaptor proteins capable of activating signaling cascades including
the MAPK pathway [14]. IGF-IR is present in a variety of brain re-
gions, and IGF-I plays an important role in neurogenesis, develop-
ment and differentiation of the nervous system, and has protective
effects in neurodegeneration and trauma [15,16]. By contrast,
chronic opioid treatment affects hippocampal neurogenesis and
plasticity in neuronal circuits [17]. It has been suggested that
growth factors, including IGF-I, could be used to reverse the
adverse effects of morphine or other opioids in humans [16].
Recently, we demonstrated that MOPr expression is dependent
on IGF-IR stimulation in neuroblastoma cells, suggesting a cross-
talk between these two receptor systems [18]. Possible transacti-
vation mechanisms at signal transduction level, in neuronal cells
expressing both receptors, have been poorly investigated.
In this study, we investigated the crosstalk between MOPr and
IGF-IR in SH-SY5Y neuroblastoma-derived cells, a suitable model
of neuronal cells expressing both these receptors [18].
2. Materials and methods
2.1. Cell culture and materials
Human neuroblastoma SH-SY5Y cells (Health Protection
Agency Culture Collections, Salisbury, Wiltshire, UK) were grown
as monolayers in minimum essential media (MEM) and Ham’s
F12 (1:1) medium supplemented with 10% (v/v) fetal calf serum
(FCS) (Lonza, Basel, Switzerland), 2 mM L-glutamine, non-essential
aminoacids solution, 100 U/mL penicillin and 100 lg/mL strepto-
mycin (Invitrogen, Carlsbad, CA, USA) in a humidiﬁed environment
containing 5% CO2 and 95% air. For experiments, cells were ﬁrst
seeded into 6-well or 24-well dishes containing complete cell cul-
ture medium with FCS for at least 24 h, and subsequently cultured
in serum-free medium for 16–18 h before experiments were car-
ried out. Recombinant human IGF-I peptide (Preprotech Inc., Rocky
Hill, NJ, USA), [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO)
and naloxone hydrochloride (both Tocris, Bristol, Avon, UK) were
dissolved in phosphate-buffered saline (PBS).
Control cells were treated with the vehicle alone (PBS). The
c-Src-speciﬁc inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)-
pyrazolo[3,4-D]pyrimidine (PP2) (Tocris) was dissolved in dime-
thylsulfoxide (DMSO; maximum 0.1% v/v). The mouse monoclonal
antibody to human IGF-IR (1H7) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). All the other reagents were
of the highest grade of purity available and were purchased from
Sigma (St. Louis, MO, USA), and the plastic consumables were pur-
chased from Sarstedt (Nümbrecht, Germany).
2.2. Small interfering RNA (siRNA)
A pre-designed and validated small interfering (si)RNA for
b-arrestin 2 and a control (CTRL) siRNA (Applied Biosystems, Foster
City, CA, USA) were transfected using a commercial reagent (Lipo-
fectamine RNAi MAX; Invitrogen) following the manufacturer’s
recommendations. SH-SY5Y cells were assayed 2 days after
transfection.
2.3. Western blotting analysis
At the end of the experiments, cell monolayers were placed on
ice, washed with ice-cold PBS and incubated in lysis buffer(50 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 2 mmol/L sodium
orthovanadate, 1% Triton X-100, 1 mmol/L phenylmethylsulfonyl
ﬂuoride) supplemented with 1X protease inhibitor cocktail (Sigma)
for 30 min at 4 C. Insoluble material was removed by centrifuga-
tion at 20,800g for 10 min at 4 C and protein concentrations
were estimated by a commercial bicinchoninic acid (BCA) assay
(Pierce, Rockford, IL, USA). Protein extracts (50 lg) were denatured
at 95 C for 3 min before being loaded and separated in SDS–PAGE
gels. The membranes were incubated overnight at 4 C with anti-
phospho-ERK 1/2 or anti-total ERK 1/2 antibodies (1:5000) (Pro-
mega, Madison, WI, USA) or anti-phospho-IGF1-R or anti-total
(not phosphorylated) IGF1-R antibody (1:1000) (Cell Signaling,
Boston, MA, USA) and, thereafter with the appropriate peroxi-
dase-conjugated secondary antibody. Digital images were acquired
and analyzed [18].
3. Results
3.1. MOPr and IGF-IR signaling converge on the ERK 1/2 pathway
It is well established that several GPCRs are able, upon agonist
activation, to stimulate the phosphorylation of MAPK by exploiting
different pathways [2]. In this study, we ﬁrst evaluated the ability
of DAMGO (10 nM–1 lM) to induce the phosphorylation of ERK 1/
2 (phosphorylated extracellular signal-regulated kinase 1/2 (pERK
1/2)), as determined by western blotting, in SH-SY5Y cells. The
experiments conﬁrmed that this MOPr agonist induces a concen-
tration-dependent increase of pERK 1/2, and the maximum effect
was observed in cells exposed to 1 lM DAMGO for 15 min. We
found that this effect was antagonized by 10 lM naloxone hydro-
chloride added 10 min before DAMGO exposure (data not shown).
The western blot analysis of time-dependent DAMGO treatment
of SH-SY5Y cells (Fig. 1a) showed that pERK 1/2 increased after
3 min of exposure to DAMGO, and peaked at 15 min, with pERK
1/2 levels returning to basal activity in cells exposed to DAMGO
for 30 min. Likewise, stimulation of IGF-IR wit 10 nM IGF-I also in-
creased pERK 1/2 accumulation in a time-dependent fashion,
reaching maximum levels after 15 min and returning to baseline
levels after 30 min (Fig. 1b). Neither DAMGO nor IGF-I altered
the total extracellular signal-regulated kinase 1/2 (tERK 1/2) pro-
tein level.
3.2. Prolonged DAMGO exposure causes homologous and heterologous
desensitization of the ERK 1/2 signaling pathway
For investigation of homologous desensitization of ERK 1/2,
SH-SY5Y cells were pre-treated with 1 lM DAMGO for 12 h, then,
after washing out the ligand, the cells were brieﬂy re-exposed
(15 min) to fresh cell culture medium containing the vehicle alone
or 1 lM DAMGO before being harvested and lysed. Using western
blot analysis of protein extracts, we found that sustained exposure
to 1 lM DAMGO caused homologous desensitization of this signal-
ing pathway; there was no detectable increase in pERK 1/2
(Fig. 1c).
The heterologous desensitization of ERK 1/2 was also investi-
gated. In cells pre-treated with DAMGO for 12 h, exposure to
10 nM IGF-I for 15 min after washing with PBS and adding fresh
medium did not increase pERK 1/2 (Fig. 1c). Therefore, prolonged
exposure to DAMGO produces both homologous and heterologous
desensitization of this second messenger pathway.
We then tested the reversibility of this signaling desensitization
by exposing SH-SY5Y cells to 1 lM DAMGO for 12 h and, subse-
quently washing them with PBS and incubating them for 12 h in
fresh medium. Afterwards, SH-SY5Y cells were re-exposed to
1 lM DAMGO for 15 min or IGF-I (10 nM for 5, 15, 30, and
Fig. 1. DAMGO- and/or IGF-I-stimulated ERK 1/2 phosphorylation in SH-SY5Y cells. Each panel contains a representative autoradiograph showing pERK 1/2 and tERK 1/2
(assayed to conﬁrm equal protein loading) in serum-starved cells (16–18 h) treated with the vehicle (CTRL) or exposed to DAMGO and/or to IGF-I, and the densitometric
analysis of the bands. Quantiﬁcation of the phosphoprotein is expressed as the ratio between the phosphorylated forms and tERK 1/2. Data are expressed as percentage level
above that of controls. Values are the mean ± S.E.M. of at least six independent experiments. (a and b) Time course of (a) 1 lM DAMGO and (b) 10 nM IGF-I. (c) Homologous
and heterologous desensitization of the ERK 1/2 signaling pathway after 12 h of treatment with 1 lM DAMGO treatment. Prolonged activation of MOPr led to the absence of
pERK 1/2 formation in SH-SY5Y cells brieﬂy (15 min) re-exposed to fresh cell culture medium containing the vehicle alone (CTRL), 1 lM DAMGO or 10 nM IGF-I before
harvesting and lysing. (d) Recovery of ERK 1/2 activity. SH-SY5Y cells treated for 12 h with DAMGO and then left in fresh medium without any ligand for 12 more h regained
ERK 1/2 pathway sensitivity when re-exposed to 1 lM DAMGO (15 min) or 10 nM IGF-I (5–60 min). ***P < 0.001; **P < 0.01 vs. CTRL; ###P < 0.001 vs. DAMGO 15 min;
§§§P < 0.001 vs. IGF-I 15 min (Newman–Keuls test after analysis of variance (ANOVA)).
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pERK 1/2 compared with the control cells (Fig. 1d). These data
demonstrate complete recovery from desensitization of MOPr
and IGF-IR in SH-SY5Y cells.
3.3. Acute DAMGO treatment transactivates IGF-IR
Upon activation, IGF-IR undertakes a measurable autophospho-
rylation process [19]. We used an antibody raised against the phos-
phorylated insulin-like growth factor I receptor (pIGF-IR) in orderto assess the variation of the phosphorylation levels within a time
span of 2 h (Fig. 2a). IGF-I (10 nM) elicits a time-dependent phos-
phorylation of IGF-IR, peaking at 15 min and then slowly returning
to baseline after 2 h of stimulation with DAMGO. Under these con-
ditions, total (t)IGF-IR protein content did not change.
Heterologous receptor crosstalk between the GPCR and RTK sys-
tems has been previously described [3]. To investigate any possible
transactivation of the IGF-IR induced by DAMGO, we exposed SH-
SY5Y cells to 10 nM IGF-I or 1 lM DAMGO for 15 min. Both treat-
ments elicited signiﬁcant phosphorylation of the IGF-I receptor
Fig. 2. IGF-I- and DAMGO-induced phosphorylation of the IGF-IR receptor in SH-SY5Y cells. In each panel, representative autoradiographs and the densitometric analysis of
the bands of the pIGF-IR are shown. Under these conditions, tGF-IR protein content did not change. (a) Time course of IGF-IR phosphorylation in cells exposed to 10 nM IGF-I.
(b) Effect of IGF-I and DAMGO on IGF-IR phosphorylation. (c) Role of Src kinase in DAMGO-induced IGF-IR phosphorylation. The c-Src inhibitor PP2 (10 lM) was dissolved in
0.1% DMSO (VEH) and added to the cells 10 min before DAMGO exposure (1 lM for 15 min). ***P < 0.001; *P < 0.05 vs. CTRL; #P < 0.05 vs. IGF-I or DAMGO alone (Newman–
Keuls test after ANOVA).
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these ligands signiﬁcantly enhanced receptor phosphorylation
compared with cells exposed to DAMGO or IGF-I alone.
It has been reported that SH-SY5Y cells produce IGF-II, which
acts via an autocrine mechanism to stimulate IGF-IR [20]. To ex-
clude the possibility that DAMGO releases IGF-II, which binds to
IGF-IR causing its autophosphorylation, a neutralizing antibody
against IGF-IR (10 nM given 15 min before DAMGO) was included
in the culture media. This did not prevent IGF-IR phosphorylation
induced by DAMGO, suggesting that a paracrine/autocrine loop is
not involved in this mechanism (data not shown).
Interestingly, activation of MOPr has been shown to stimulate
c-Src tyrosine kinase in SH-SY5Y cells [21]. Furthermore, this ki-
nase phosphorylates and activates IGF-IR [22]. Therefore, we
examined the function of c-Src kinase on DAMGO-mediated IGF-
IR phosphorylation. Serum-starved SH-SY5Y cells were pre-treated
with the c-Src selective inhibitor PP2 (10 lM) or with the vehicle
alone containing 0.1% DMSO, before stimulation with 1 lM DAM-GO for 15 min. We found that in cells exposed to PP2, DAMGO
did not induce any signiﬁcant phosphorylation of IGF-IR (Fig. 2c).
In agreement with other studies [21,23], we also found that DAM-
GO- or IGF-I-mediated accumulation of pERK 1/2 was signiﬁcantly
reduced by PP2 (data not shown). These latter data suggest that
MOPr-mediated c-Src kinase activation may play multiple roles
in regulating ERK phosphorylation, acting both before and/or after
IGF-IR transactivation.
3.4. b-Arrestin 2 mediates IGF-IR transactivation and its heterologous
desensitization
Using a siRNA directed against b-arrestin 2, we investigated the
inﬂuence of this cytoplasmic protein to mediate the signaling from
the activated MOPr receptor to IGF-IR in the transactivation pro-
cess. In agreement with Kim et al. [24], cell transfection with
20 lg of siRNA for b-arrestin 2 effectively and speciﬁcally reduced
its expression by approximately 70% (Fig. 3). As already shown
Fig. 3. b-Arrestin 2 down-regulation induced by siRNA. SH-SY5Y cells were transfected with a siRNA (20 lg) designed and validated against b-arrestin 2 or with a CTRL siRNA.
(a) A representative western blotting experiment showing a noteworthy reduction of b-arrestin 2 in SH-SY5Y cells exposed for 48 h to b-arrestin 2 siRNA compared with cells
treated with CTRL siRNA or vehicle alone (CTRL). b-Actin was evaluated in the same samples and used as loading control. (b) Densitometric analysis of the bands. Values are
mean ± S.E.M. of at least six independent experiments. ***P < 0.001 vs. CTRL or to cells treated with CTRL siRNA (Newman–Keuls test after ANOVA).
Fig. 4. b-Arrestin 2 silencing by siRNA counteracts DAMGO-induced heterologous desensitization of IGF-I-activated ERK 1/2 and IGF-IR phosphorylation. SH-SY5Y cells were
transfected with a siRNA (20 lg) against b-arrestin 2 or with CTRL siRNA (siRNAc; 20 lg) and treated 48 h later as described in the text. (a) Representative autoradiographs
showing pERK 1/2 and tERK 1/2 (assayed to conﬁrm equal protein loading) in serum-starved cells (16–18 h) treated with the vehicle (CTRL) or exposed to 1 lM DAMGO for
12 h and/or to IGF-I 10 nM for 15 min, and the densitometric analysis of the bands. Quantiﬁcation of the phosphoprotein is expressed as the ratio between the phosphorylated
forms and tERK 1/2. (b) Representative autoradiographs and the densitometric analysis of the bands of the pIGF-IR. In these conditions, total insulin-like growth factor I
receptor (tIGF-IR) protein content did not change. Data are expressed as percentage above the controls. Values are the mean ± S.E.M. of at least six independent experiments.
***P < 0.001 compared with CTRL or cells treated with DAMGO 12 h plus CTRL siRNA plus IGF-I (Newman–Keuls test after ANOVA).
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prolonged MOPr activation was characterized by the lack of accu-
mulation of pERK 1/2; however, after silencing b-arrestin 2, IGF-I
stimulation (10 nM for 15 min) of SH-SY5Y cells induced phos-
phorylation of ERK 1/2 even after prolonged exposure to DAMGO
(1 lM for 12 h) (Fig. 4a). To investigate whether the convergence
on this signaling pathway involves IGF-IR activation, we measured
the phosphorylation of this receptor after b-arrestin 2 siRNA silenc-
ing. We found that b-arrestin 2 silencing impaired the transfer of
the signaling from MOPr to IGF-IR (Fig. 4b). Therefore, IGF-IR doesnot seem to be inﬂuenced any longer by prolonged treatment with
DAMGO and can be phosphorylated upon IGF-I exposure. Thus,
heterologous desensitization of IGF-IR signaling seems to be
dependent on the scaffolding properties of b-arrestin 2.
4. Discussion
In this paperwe demonstrate, for the ﬁrst time to our knowledge,
that aMOPr agonist transactivates IGF-IR.Moreover, prolonged acti-
vation of MOPr signaling causes the heterologous desensitization of
A. Spartà et al. / FEBS Letters 584 (2010) 3580–3586 3585IGF-IR as evidencedby the lack of IGF-IR phosphorylation and ERK1/
2 activationby IGF-I. Previous investigation of the crosstalk between
these two systems has deﬁned the role of c-Src kinase and b-arrestin
2 in signaling transfer fromMOPr to IGF-IR.
The aptitude of some GPCRs to transactivate RTKs [2] suggests
their ability to share some growth factor-like effects, including
activation of ERK 1/2. Proteins in the Src tyrosine kinase family
have been suggested to function as upstream mediators of RTK
transactivation in response to stimulation by GPCRs [25]. Based
on our ﬁndings, we hypothesize that c-Src can be recruited to
the MOPr upon agonist binding, in a b-arrestin-dependent manner
[10], and play a role in DAMGO-mediated IGF-I transactivation and
ERK activation.
The role of b-arrestin 2 in GPCR desensitization is very well con-
solidated [6,7]; moreover, recent ﬁndings have demonstrated the
ability of b-arrestins to interact with cytoplasmic effectors that
can phosphorylate cytoskeletal or plasma membrane targets
[7,8]. Interestingly, it has also been recently demonstrated that a
feedback loop of phosphorylation exists between the activated
ERKs and EGFR, which is consequent to MOPr activation and de-
pends on the length of exposure, the state of the receptor oligo-
merization and the speciﬁc ligand in use [11]. The
conformational stabilization of the MOPr resulting from binding
with an agonist favors the phosphorylation of MOPr by G-protein
coupled receptor kinases and its subsequent binding to b-arrestins,
which uncouple the receptor from the Gi/o protein, blocking the
intracellular signaling [12,13]. The lack of IGF-IR phosphorylation
after DAMGO stimulation in b-arrestin 2-silenced SH-SY5Y cells re-
ﬂects the importance of this cytoplasmic protein in the transactiva-
tion of IGF-IR by MOPr. It thus appears that several signaling
mechanisms can cooperate to mediate MOPr and IGF-IR crosstalk
in SH-SY5Y cells, and that these converge on transactivation of
the IGF-IR and ERK activation.
In agreement with this idea, several studies have suggested that
IGF-IR may act as intermediate for other GPCRs, including the type
1 receptor of angiotensin II [26] and the GABAB receptor [27]. Fur-
thermore, it has been reported that IGF-I may induce heterologous
desensitization of GPCRs by downregulating b-arrestin 1 [28];
however, whether activation of GPCRs can lead to heterologous
desensitization of IGF-IR-mediated signaling has been poorly
investigated.
Desensitization mechanisms play an important role in opioid
tolerance development [29]. Both the cAMP-protein kinase A and
MAPK cascades have been deeply explored [30] but cell adaption
to a prolonged exposure to MOPr agonists involves other kinase
families, including protein kinase C [31]. However up to now only
ERK 1/2, members of the MAPK family, appear to be activated via
EGFR transactivation and desensitized following a prolonged expo-
sure to EGFR agonists [4]. Moreover, ERK 1/2 activation by MOPr
may involve the crosstalk with several RTKs as MOPr agonists are
capable to transactivate the platelet-derived growth factor-beta
receptor [32] and the ﬁbroblast growth factor receptor [33]; thus,
this crosstalk may contribute to modulate signaling pathways
involving ERK 1/2 in cells co-expressing MOPr and various RTKs.
MOPr and IGF-IR are widely distributed in the nervous system
[34,35] and it could be suggested that both receptors may be colo-
calized in neuronal cells as well as they are co-expressed in the cel-
lular model adopted in this study. Cellular models, in fact, have
been widely employed to study possible cross-communications
between GPCRS and RTKs [36]; however further investigations,
which employ appropriate in vivo models, occur to conﬁrm and ex-
tend present observations.
Many reports have demonstrated the importance of growth fac-
tors in neuronal development and in the adult brain [15,37].
Administration of growth hormone and IGF-I improves many psy-
chological and physiological parameters, including attention andcognitive functions [16]. By contrast, deﬁciencies in this signaling
process impair important cognitive functions, particularly atten-
tion and memory [37]. Growth factor receptors activate, among
others, the MAPK pathways that phosphorylate cytoplasmic tar-
gets, which, in their turn, can translocate to the nucleus where they
bind to speciﬁc response elements on DNA to modulate gene tran-
scription. Thus, we propose that prolonged exposure to MOPr ago-
nists may cause signiﬁcant heterologous desensitization of IGF-IR
co-expressed in the same cells with consequences for IGF-IR-med-
iated cell signaling.
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